| 翻訳と辞書 |
Etravirine
Etravirine (ETR,〔(【引用サイトリンク】Department of Health and Human Services ">work=Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents )〕 brand name Intelence, formerly known as TMC125) is a drug used for the treatment of HIV. Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). Unlike the currently available agents in the class, resistance to other NNRTIs does not seem to confer resistance to etravirine. Etravirine is marketed by Tibotec, a subsidiary of Johnson & Johnson. In January 2008, the Food and Drug Administration approved its use for patients with established resistance to other drugs, making it the 30th anti-HIV drug approved in the United States and the first to be approved in 2008.〔(【引用サイトリンク】title=FDA Approves HIV Drug Etravirine )〕 It was also approved for use in Canada on April 1, 2008.
Etravirine is licensed in the United States, Canada, Israel, Russia, Australia and the European Union,〔(【引用サイトリンク】publisher=Tibotec )〕 and is under regulatory review in Switzerland.〔(【引用サイトリンク】publisher=aidsmap )〕
==Indications and dosage==
Etravirine, in combination with other anti-retrovirals, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients, who have evidence of viral replication and HIV-1 strains resistant to a non-nucleoside reverse transcriptase inhibitor (NNRTI) and other antiretroviral agents.
The recommended dose of etravirine is 200 mg (2 x 100 mg tablets, or 1 x 200 mg tablet as of 03/18/2011) taken twice daily following a meal. The type of food does not affect the exposure to etravirine.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Etravirine」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|